Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-G3-ABD
- Development stage
- Preclinical
- Lead developer
- Affibody
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
177Lu-G3-ABD is a preclinical radiopharmaceutical designed for targeted radionuclide therapy of human epidermal growth factor receptor 2 (HER2)-expressing malignancies. The agent consists of the HER2-targeting designed ankyrin repeat protein (DARPin) G3 fused at its C-terminus to an albumin-binding domain (ABD), conjugated with a DOTA chelator, and radiolabeled with the beta-emitting isotope lutetium-177 (177Lu). While small scaffold proteins like DARPins typically suffer from rapid renal clearance and high kidney reabsorption, the fusion of the ABD allows the construct to bind to serum albumin in circulation. This interaction significantly extends the blood half-life, reduces renal accumulation, and enhances tumor uptake, thereby optimizing the therapeutic index for treating HER2-positive cancers such as breast and ovarian cancers.
- Other names
- 177Lu-DARPin G3-ABD177Lu-DOTA-G3-ABD177Lu-labeled G3-ABD[177Lu]Lu-G3-ABDlutetium Lu 177 G3-ABDlutetium-177 G3-ABDlutetium177 G3-ABDlutetium 177 G3-ABD
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 177Lu-G3-ABD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-G3-ABD.